Cocrystal Pharma, Inc. Completes Up to $13 Million Registered Direct Offering at Market Price in Accordance with Nasdaq Regulations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 15 2025
0mins
Source: Globenewswire
Offering Details: Cocrystal Pharma, Inc. closed a registered direct offering of 2,764,710 shares at $1.70 per share, raising approximately $4.7 million, with potential additional proceeds of about $8.3 million from unregistered warrants.
Use of Proceeds: The company plans to use the net proceeds from the offering for working capital and general corporate purposes, while the unregistered warrants are not registered under the Securities Act and cannot be sold in the U.S. without proper registration.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
